Roth Capital Reaffirms TG Therapeutics (TGTX) at 'Buy'; Still Sees TGR-1202, TG-1101 as Well Positioned
Roth Capital affirms TG Therapeutics (Nasdaq: TGTX) with a Buy/Focus Pick rating and $33 price target following Q3 results and ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)